skip to Main Content

Next-Generation Antibody Therapies

We develop our therapeutic candidates using our DiversImmune™ platform. Our antibody discovery platform enables us to generate antibodies against traditionally difficult targets. The resulting antibodies are high affinity, high specificity antibody “building blocks” with drug-like properties against a wide range of therapeutic targets. Our platform then enables us to assemble these building blocks into a variety of formats, tailored for each disease area.

We are focusing on areas where we can help mankind affected by serious disease and where monoclonal antibodies can play a leading role. This includes immuno-oncology/cancer, eye, infectious, and autoimmune disease.

DiversImmune™ Antibody Discovery Platform

Our DiversImmune™ platform was built to address a key bottleneck in the antibody therapeutics industry: the ability to rapidly generate high affinity and high specificity antibodies against virtually any target of interest. To date, our DiversImmune™ platform has been extensively validated by generating high quality antibodies for pharmaceutical and biotechnology companies against more than 300 different targets. The DiversImmune™ platform comprises three key steps, all focused on generating a diverse collection of high quality antibodies:

  • Immunization.We leverage the latest technologies, methods, and know-how to generate a strong immune response from which to create monoclonal antibodies with the key therapeutic properties that are needed. This includes a variety of co-stimulation methods to optimize the immune response to each target and yield a diverse collection of antibodies that recognize different epitopes, or binding regions, on the same target protein. 
  • Diversification. We leverage the broad immune repertoire of a natural immune system to create large panels of monoclonal antibodies. These are then optimized on our platform for desired therapeutic properties, using the latest in antibody technologies and techniques. 
  • Optimization. Once the initial antibodies are created, these comprise the building blocks to create a therapy needed. Each disease area is unique and has specific requirements. Our platform is able to generate these formats quickly through technology.

MultiMab™ Antibody Engineering Platform

Using antibody building blocks arising from our DiversImmune platform, our MultiMab platform enables us to build a diverse array of bi- and multi-specific antibodies. This allows us to rapidly optimize the formats of our therapeutic product candidates. Because biology is diverse and complex, there is no “one size fits all” solution to engineering multi-specific antibodies. Instead, different problems call for different solutions. We draw from a suite of different antibody formats to choose the one that best suits the disease and mechanism we are targeting. Despite having multiple formats from which to choose, our formats typically contain two key features:

  • Bivalent binding. Bivalent binding, or binding with two points of contact, takes advantage of the concept of avidity, specifically that multipoint connections are much stronger than single point connections. In order to maximize efficacy, we build bivalent binding into our therapeutic product candidates where increased strength of binding is desirable.
  • Fc region. The Fc region of an antibody interacts with various receptors on immune cells to control both the immune response to antibody binding and the circulating half-life of an antibody. To take advantage of these natural functions, we build Fc regions into all our therapeutic product candidates.

TetraBi Antibody Format for T-cell Engagement

Every day, immune cells scan your body for problems and eliminate cells that they sense are foreign. Even cells that would otherwise form cancer are routinely eliminated by your immune system. One of the most promising strategies in cancer therapy is to direct cytotoxic T cells to kill tumor cells. This can be achieved using dual-targeting antibodies, which bind simultaneously to a tumor-specific antigen on a tumor cell and to CD3 on a T cell, bringing these cells into close proximity and causing the T cell to kill the tumor cell.

We are building a pipeline of T-cell engagers based on a tetravalent bispecific (TetraBi) format. The TetraBi format of our ABP-100 series of product candidates offers several significant advantages over other bispecific antibody formats and other approaches to T cell-based therapy.

  • Enhanced potency through bivalent binding to tumor cells. By including two binding sites for the tumor antigen, our antibodies are designed to form a much stronger connection to tumor cells than molecules that feature only a single binding site.
  • Enhanced safety through functionally monovalent binding to CD3. By placing the CD3-binding domain in the hinge region of the molecule, our antibodies behave as if they have a single binding site for CD3. This is important to prevent TetraBi antibodies from activating T cells in the absence of tumor cells, which could lead to unwanted toxicities such as cytokine release syndrome.
  • Better dosing through inclusion of an Fc region. By including an Fc region, our TetraBi antibodies are designed to have long circulating half-lives, enabling more convenient dosing for patients.
  • Controlled immune effector function through Fc engineering. By introducing defined mutations into the Fc region, our TetraBi antibodies are designed to diminish or eliminate Fc-mediated interactions that can contribute to unwanted side effects, such as cytokine release syndrome.
  • Lower immunogenicity. By closely resembling natural human antibodies, our TetraBi antibodies have a reduced risk of being immunogenic, which could otherwise lead to decreased efficacy.
  • Streamlined manufacturing. By building symmetrical molecules with two identical heavy chains and two identical light chains, our molecules are designed to eliminate complications arising from potential chain mispairing.
Back To Top